Dana-Farber Cancer Institute | Strategic Alliance Partners

August 28, 2018

Sara M. Tolaney, MD, MPH, discusses developments in the treatment paradigms for patients with HR-positive or HER2-positive breast cancer.

August 24, 2018

Noopur Raje, MD, discusses the latest treatment advances in multiple myeloma.

August 22, 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the role of chemotherapy in the treatment of patients with HER2-positive breast cancer.

August 21, 2018

Nikhil C. Munshi, MD, discusses the current treatment landscape of myeloma and potential next steps to further advancing care.

August 17, 2018

Ursula A. Matulonis, MD, highlights the activity and tolerability of niraparib and discusses other recent data in ovarian cancer.

August 17, 2018

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the quality-of-life outcomes from the GOG-258 trial in patients with endometrial cancer.

August 16, 2018

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the latest treatment developments for patients with multiple myeloma.

August 15, 2018

Jennifer Ligibel, MD, senior physician, Susan F. Smith Center for Women's Cancer at the Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the resources available for patients to educate themselves on avoiding breast cancer recurrence.

August 09, 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses selecting patients with estrogen receptor (ER)-positive breast cancer for treatment with CDK4/6 inhibitors.

August 09, 2018

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses a trial of tazemetostat in pediatric patients with INI1-negative tumors.

August 03, 2018

Rinath M. Jeselsohn, MD, discusses the detection and clinical implications of ESR1 mutations.

August 01, 2018

Jennifer Ligibel, MD, senior physician, Susan F. Smith Center for Women’s Cancer at the Dana-Farber Cancer Institute, discusses the impact of diet and exercise on the risk of breast cancer recurrence.

July 26, 2018

Toni K. Choueiri, MD, discusses some of the most significant data presented thus far in 2018 for the treatment of patients with renal cell carcinoma.

July 25, 2018

Panagiotis A. Konstantinopoulos, MD, PhD, director, Translational Research, Gynecologic Oncology, Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the rationale behind the TOPACIO trial for the treatment of patients with recurrent ovarian cancer.

July 24, 2018

Ursula A. Matulonis, MD, chief, Division of Gynecological Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the rationale behind the QUADRA trial for patients with relapsed ovarian cancer.

July 23, 2018

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses pediatric atypical teratoid rhabdoid tumors.

July 23, 2018

David A. Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, discusses pembrolizumab (Keytruda) and bevacizumab (Avastin) for the treatment of patients with recurrent PD-L1–positive glioblastoma.

July 18, 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the phase Ib results of abemaciclib (Verzenio) plus pembrolizumab (Keytruda) for hormone receptor-positive, HER2-negative metastatic breast cancer.

July 13, 2018

Paul Richardson, MD, discusses the efficacy and tolerability of the combination of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone in patients with multiple myeloma.

July 04, 2018

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses checkpoint inhibitors in renal cell carcinoma (RCC).